Sunday, August 28, 2016 8:10:56 PM
I could not stand further ...
Corsicanto: It is a 100% (fully) owned subsidiary of Amarin. A different entity legally, but technically equal with Amarin. All SEC report include Corsicanto's (and other subsidiaries) activity. It is called as consolidated report. e.g. 2012 Notes (see below) was reported from day one.
Notes:
- 2012: $150M (CORSICANTO LIMITED, as Issuer, AMARIN CORPORATION PLC, as Guarantor)
- 2014: $118.734M of 2012 Notes were converted (CORSICANTO LIMITED, as Issuer, AMARIN CORPORATION PLC, as Guarantor)
- 2015: $31.266M (AMARIN CORPORATION PLC, as Issuer, no Guarantor). The Notes were 100% subscribed by BAKER BROTHERS and partially ($15.2M) was used to repay 2012 Notes
All Notes are / were hold by 3rd parties, not by Corsicanto or Amarin. With a current exchange the remaining balance is $15.066M (as 2012 Notes) by 3rd parties, not by Corsicanto or Amarin and all shares go to 3rd parties, not to Corsicanto or to Amarin.
The notes are / were exchangeable to shares by:
- Holder (3rd party): anytime
- Amarin / Corsicanto: 20-day $2.86 within any 30 days (it is the short version only ...)
Exchange price: $2.60 (independently from the actual PPS. $2.86 was a threshold only for Amarin to exercise exchange option).
Timing: it was the first time, when Amarin could exercise the exchange option. Again: the exchange rate isn't / won't be affected by actual PPS (top of Additional shares: depends on PPS and timing, see 2014 Notes page 57, less than 30.0937 / $1,000 Notes)
"mandatory": applicable for the Holders, they could not deny the exchange. They could not force / request it from Amarin:
a.) it was a sole discretion of Amarin
b.) if they want, they could request the exchange ANYTIME, independently from PPS, since the threshold was applicable to Amarin only
September 12: is the effective date (of the exchange)
Why?: Why not (if possible)? If the Holders do not want to get back the money, but want the exchange, Amarin could not pay back the Notes. (Holders have an option to choose exchange in case of redemption.) If R-IT will be successful and PPS will go north the Holder will exercise their exchange option and they would get the same amount of shares (since - again - it is independent from PPS top of Additional shares). Why pay more interest, if it isn't necessary ... exchange now. EOS
I hope it ends the tzunami of nonsenses ... If you have a question feel free to address ...
- - - - -
"Kalb"
He joined to the Co by June 30 this year. All who thinks he has a material influence on the recent events (especially who thinks he initiated these) does not have a clue about how it works at a Company. Never works at a Co or if yes not as a member of the management ... To predict / expect something based on his previous job (e.g. share buy back) is foolish ... a good CFO will do that is the best fit to the Co (to the current and not to the previous ...), but strategy, material event decided / approved by CEO (BOD) always ...
Best,
G
#STRONGERTOGETHER
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Recent AMRN News
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM